
Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91-22) 4324 4343 Website: <u>www.sunpharma.com</u> CIN: L24230GJ1993PLC019050



National Stock Exchange of India Limited, Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai- 400 051

Scrip Symbol: SUNPHARMA

BSE Limited, Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001

Scrip Code: 524715

Sub: Acquisition of trademarks and patent license for Dapagliflozin and its combinations from AstraZeneca AB by Sun Pharma and its subsequent change in business relationship under the Distribution Services Agreement, 2016 ("Distribution Agreement") with AstraZeneca Pharma India Limited

Dear Sir / Madam,

We refer to our announcement of March 23, 2016, wherein we had informed about the Distribution Agreement between Sun Pharma Laboratories Limited (Sun Pharma), the wholly owned subsidiary of Sun Pharmaceutical Industries Limited, and AstraZeneca Pharma India Limited (AstraZeneca India) for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India.

Under the said agreement, AstraZeneca India had granted rights to Sun Pharma to promote and distribute Dapagliflozin under the brand name "Oxra[®]". Sun Pharma also gained the rights to promote and distribute the combination of Dapagliflozin with Metformin under the brand name "Oxramet[®]" and the combination of Dapagliflozin and Saxagliptin under the brand name "Oxraduo[®]". The said Distribution Agreement had conferred only a license to Sun Pharma for the use of trademarks "Oxra[®]", "Oxramet[®]" and "Oxraduo[®]" in India.

Sun Pharma has now acquired the rights to Trademarks "Oxra[®]", "Oxramet[®]" and "Oxraduo[®]" in India from AstraZeneca AB, Sweden, parent company of AstraZeneca Pharma India Limited, with effect from 28th May 2021. In addition Sun Pharma has also taken a patent license to manufacture and commercialize Dapagliflozin and Dapagliflozin with Metformin combination in India from AstraZeneca AB with effect from 28th May 2021.

Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021.

Under the Transition Supply Agreement, AstraZeneca India will supply Dapagliflozin and the combination of Dapagliflozin with Metformin to Sun Pharma until such period of time as mutually agreed between the parties, post which all supplies to Sun Pharma from AstraZeneca India shall cease.

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA



Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91-22) 4324 4343 Website: www.sunpharma.com CIN: L24230GJ1993PLC019050



Other terms and conditions of the agreement are confidential.

This is for your information and necessary dissemination.

Thanking you,

Yours faithfully,

For Sun Pharmaceutical Industries Limited

Ashok I. Bhuta Compliance Officer